Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma

NCT01897714 is registered in ClinicalTrials.gov with Oncopeptides AB as lead sponsor.

NCT NCT01897714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01897714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma
Lead sponsor
Oncopeptides AB
Phase
Phase 1/2
Overall status
Terminated
Start date
July 31, 2013
Completion date
March 31, 2020
Enrollment
75 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or relapsed-refractory multiple myeloma